Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 5, 2012, Pages 587-599

  Chey, W D ^a   Drossman, D A ^b   Johanson, J F ^c   Scott, C ^d   Panas, R M ^d   Ueno, R ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d Sucampo Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; LUBIPROSTONE; PLACEBO; SIB 0431; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BIOCHEMISTRY; BLADDER DISEASE; BODY MASS; BODY WEIGHT; BREAST DISEASE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GENITAL INJURY; HEALTH STATUS; HEMATOLOGICAL PARAMETERS; HUMAN; INFESTATION; INJURY; INTOXICATION; IRRITABLE COLON; IRRITABLE COLON WITH CONSTIPATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VITAL SIGN; VOMITING;

ACTIVITIES OF DAILY LIVING; ADULT; ALPROSTADIL; CHLORIDE CHANNELS; CONSTIPATION; DEFECATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856707088     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04983.x     Document Type: Article

References (17)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al,. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl. 1): S1-35.
3. Saito YA., Locke GR., Talley NJ., et al,. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 2816-24.
4. Saito YA, Schoenfeld P, Locke GR 3rd,. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-5.
5. Quander C, Morris MC, Bienias JL, Evans DA,. Prevalence of irritable bowel syndrome in an older bi-racial population [Abstract 1085]. Am J Gastroenterol 2007; 102: S516.
6. Locke GR., Clark S., Cerulli A., et al,. Work productivity is more impaired in functional gastrintestinal disorders compared to GERD: six-month data from PROGRESS [abstract 1052]. Am J Gastroenterol 2007; 102: S504.
7. Drossman DA., Chey WD., Panas R., et al,. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials [abstract]. Gastroenterology 2007; 132: 639f.
8. Drossman DA, Chey WD, Johanson JF, et al,. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
9. Drossman DA, Patrick DL, Whitehead WE, et al,. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 999-1007. (Pubitemid 30196737)
10. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL,. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11. (Pubitemid 28124621)
11. Guo Z, Gill TM, Allore HG,. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med 2008; 47: 107-16. (Pubitemid 351438400)
12. Camilleri M, Bharaucha AE, Ueno R, et al,. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-7.
13. Cuppoletti J, Malinowska DH, Tewari KP, et al,. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1178-83.
14. Moeser AJ., Nighot PK., Engelke KJ., Ueno R, Blikslager AT,. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007; 292: G647-56.
15. Camilleri M, Gorman H,. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 545-52. (Pubitemid 46985594)
16. Johanson JF, Morton D, Geenen J, Ueno R,. Multicenter, four-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-7.
17. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R,. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-96. (Pubitemid 351406304)